Thilo Zander

1.0k total citations
25 papers, 308 citations indexed

About

Thilo Zander is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Thilo Zander has authored 25 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in Thilo Zander's work include Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Thilo Zander is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Thilo Zander collaborates with scholars based in Switzerland, Germany and Austria. Thilo Zander's co-authors include Stefan Aebi, Oliver Gautschi, Joachim Diebold, Klaus Strobel, Astrid Hirschmann, Thomas Pabst, Juergen Wolf, S. Wiedenmann, Daniel Betticher and Urban Novak and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Thilo Zander

23 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thilo Zander Switzerland 10 143 112 95 70 61 25 308
Su Y. Kim United States 9 88 0.6× 99 0.9× 119 1.3× 63 0.9× 87 1.4× 11 391
Subhayan Chattopadhyay Sweden 11 125 0.9× 49 0.4× 71 0.7× 105 1.5× 41 0.7× 37 321
Jennifer L. Cultrera United States 8 202 1.4× 63 0.6× 54 0.6× 182 2.6× 24 0.4× 23 326
Valentina Bozzoli Italy 8 123 0.9× 36 0.3× 49 0.5× 160 2.3× 85 1.4× 17 345
Lokanatha Dasappa India 9 106 0.7× 40 0.4× 36 0.4× 52 0.7× 44 0.7× 41 257
Hari A. Deshpande United States 10 136 1.0× 90 0.8× 120 1.3× 38 0.5× 32 0.5× 46 363
Mayur Narkhede United States 8 131 0.9× 34 0.3× 63 0.7× 124 1.8× 143 2.3× 40 320
Byung Woog Kang South Korea 10 241 1.7× 193 1.7× 66 0.7× 41 0.6× 38 0.6× 21 406
Yayan Zhang United States 7 331 2.3× 78 0.7× 65 0.7× 142 2.0× 61 1.0× 10 440

Countries citing papers authored by Thilo Zander

Since Specialization
Citations

This map shows the geographic impact of Thilo Zander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thilo Zander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thilo Zander more than expected).

Fields of papers citing papers by Thilo Zander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thilo Zander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thilo Zander. The network helps show where Thilo Zander may publish in the future.

Co-authorship network of co-authors of Thilo Zander

This figure shows the co-authorship network connecting the top 25 collaborators of Thilo Zander. A scholar is included among the top collaborators of Thilo Zander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thilo Zander. Thilo Zander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beck, Philipp, Ulrike Bacher, Katja Seipel, et al.. (2023). BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia. Journal of Clinical Medicine. 12(6). 2378–2378.
2.
Zander, Thilo, Thomas Pabst, Sämi Schär, et al.. (2023). Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia. 37(3). 699–701. 1 indexed citations
3.
Bacher, Ulrike, et al.. (2022). Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. Cancers. 15(1). 44–44. 4 indexed citations
4.
Bacher, Ulrike, et al.. (2022). Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial. Bone Marrow Transplantation. 57(6). 990–997. 9 indexed citations
5.
Aebi, Stefan, et al.. (2022). Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance. BMJ Case Reports. 15(4). e246264–e246264. 6 indexed citations
6.
Samaras, Panagiotis, Mario Bargetzi, Daniel Betticher, et al.. (2019). Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Medical Weekly. 149(1314). w20031–w20031. 4 indexed citations
7.
Bargetzi, Mario, Sergio Cogliatti, Pierre‐Yves Dietrich, et al.. (2018). Diagnosis and treatment of follicular lymphoma: an update. Swiss Medical Weekly. 148(2930). w14635–w14635. 13 indexed citations
8.
Zander, Thilo, Stefan Aebi, Thomas Pabst, Christoph Renner, & Christoph Driessen. (2017). Spotlight on pomalidomide: could less be more?. Leukemia. 31(9). 1987–1989. 5 indexed citations
9.
Novak, Urban, Behrouz Mansouri Taleghani, Gabriela M. Baerlocher, et al.. (2016). BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Annals of Hematology. 96(3). 421–429. 25 indexed citations
10.
11.
Zander, Thilo, Stefan Aebi, Anna Christina Rast, et al.. (2016). Response to Pembrolizumab in a Patient with Relapsing Thymoma. Journal of Thoracic Oncology. 11(12). e147–e149. 35 indexed citations
12.
Samaras, Panagiotis, Mario Bargetzi, Daniel Betticher, et al.. (2015). Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Medical Weekly. 145(708). w14100–w14100. 4 indexed citations
13.
Zimmerli, Stefan, Franziska Suter‐Riniker, Beatrice U. Mueller, et al.. (2015). Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplantation. 50(4). 573–578. 14 indexed citations
14.
Fischli, Stefan, Stephanie Allelein, Thilo Zander, & Christoph Henzen. (2014). Endokrinologische Nebenwirkungen einer onkologischen Therapie mit Anti-CTLA-4-Antikörpern. DMW - Deutsche Medizinische Wochenschrift. 139(19). 996–1000. 6 indexed citations
15.
Gautschi, Oliver, Thilo Zander, Klaus Strobel, et al.. (2013). A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib. Journal of Thoracic Oncology. 8(5). e43–e44. 72 indexed citations
16.
Toggweiler, Stefan, et al.. (2012). The Clinical Value of Echocardiography and Acoustic Cardiography to Monitor Patients Undergoing Anthracycline Chemotherapy. Clinical Cardiology. 36(4). 201–206. 5 indexed citations
17.
Höfer, Silvia, Katarzyna Elandt, Richard Greil, et al.. (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncologica. 50(5). 630–635. 36 indexed citations
18.
Nogová, Lucia, Thilo Zander, Saša Dimitrijević, et al.. (2008). Pharmacodynamics of RAD001 measured by early FDG PET in patients with recurrent NSCLC. Journal of Clinical Oncology. 26(15_suppl). 14616–14616. 4 indexed citations
19.
Zander, Thilo, et al.. (2007). Gastric pneumatosis following polychemotherapy. European Journal of Internal Medicine. 18(3). 251–252. 7 indexed citations
20.
Zander, Thilo, S. Wiedenmann, & Juergen Wolf. (2002). Prognostic factors in Hodgkin's lymphoma. Annals of Oncology. 13. 67–74. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Su Y. Kim Breakdown of academic impact, for papers by Subhayan Chattopadhyay Breakdown of academic impact, for papers by Jennifer L. Cultrera Breakdown of academic impact, for papers by Valentina Bozzoli Breakdown of academic impact, for papers by Lokanatha Dasappa Breakdown of academic impact, for papers by Hari A. Deshpande Breakdown of academic impact, for papers by Mayur Narkhede Breakdown of academic impact, for papers by Byung Woog Kang Breakdown of academic impact, for papers by Yayan Zhang
Rankless by CCL
2026